Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques ; MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford and NIHR Oxford Biomedical Research Center, Oxford OX3 9DU, United Kingdom
Language :
English
Title :
Gene therapy for spinal muscular atrophy: timing is key.
Finkel, R.S., Mercuri, E., Darras, B.T., et al., ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377 (2017), 1723–1732.
Govoni, A., Gagliardi, D., Comi, G.P., Corti, S., Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol 55 (2018), 6307–6318.
Weiß, C., Becker, L., Friese, J., et al. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH region: a population-based observational study. Lancet Reg Health Eur, 47, 2024, 101092, 10.1016/j.lanepe.2024.101092.
Gowda, V., Atherton, M., Murugan, A., et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from six infusion centres in the United Kingdom. Lancet Reg Health Eur, 37, 2024, 100817.
Vrščaj E, Dangouloff T, Osredkar D, Servais L. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscular Dis. In press. DOI 10.1177/22143602241288095.
Aragon-Gawinska, K., Mouraux, C., Dangouloff, T., Servais, L., Spinal muscular atrophy treatment in patients identified by newborn screening—a systematic review. Genes, 14(7), 2023, 1377.
Schwartz, O., Vill, K., Pfaffenlehner, M., et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Pediatr 178 (2024), 540–547.
Olkhovych, N., Gorovenko, N., Servais, L., Universal newborn screening for spinal muscular atrophy in Ukraine. Lancet 402:10398 (2023), 288–289.
Proud, C.M., Mercuri, E., Finkel, R.S., et al. Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification. Ann Clin Transl Neurol 10:11 (2023), 2155–2160.
Dangouloff, T., Hiligsmann, M., Deconinck, N., et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol 65:1 (2023), 67–77.
